Articles From: Correction to Deutsche Bank Story to Delta Redefines Cabin, Upgrades Premium Economy Options


2014/12/8
"Manhattan U.S. Attorney Files Suit Against Deutsche Bank," at 3:57 p.m. EST, misspelled the name of Deutsche Bank in the last paragraph.
Sign-up for Correction to Deutsche Bank Story investment picks
Cubist Pharmaceuticals Inc. (CBST) projects global annual revenue of $2 billion by 2017.
Sign-up for Correction to Merck-Cubist Deal Story investment picks
CHONGQING, China , Dec.
Sign-up for Country Style Cooking Restaurant Chain Announces Strategic Cooperation with Yimutian investment picks
2014/12/8
CP addresses North Dakota agriculture conference, speaks to supply chain innovation Canada NewsWire CALGARY , Dec.
Sign-up for CP addresses North Dakota agriculture conference, speaks to supply chain innovation investment picks
2014/12/8
CALGARY , Dec.
Sign-up for CP addresses North Dakota agriculture conference, speaks to supply chain innovation investment picks
2014/12/8
(FROM THE WALL STREET JOURNAL 12/9/14) By John Kester --
Sign-up for Credits & Debits investment picks
BILLERICA, Mass., Dec.
Sign-up for CSP Inc. Announces Key Executive Management Team Appointment investment picks
SAN DIEGO, Calif., Dec.
Sign-up for Cubic Awarded SPAWAR Contract to Supply Common Data Links investment picks
Cubist Pharmaceuticals, Inc .
Sign-up for Cubist Comments on CUBICIN Patent Litigation investment picks
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) breached their fiduciary duties in connection with the planned merger of the Company with Merck & Co., Inc. Cubist is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment.
Sign-up for CUBIST PHARMACEUTICALS ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck investment picks
2014/12/8
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc. (“Cubist”) (NASDAQ GS:CBST) concerning the sale to Merck & Co., Inc. Under the terms of the agreement, Cubist shareholders will receive $102.00 in cash for each share owned, which is only a 37% premium over the share price just before the deal was announced and only a slight premium over the 52-week high.
Sign-up for CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Merck & Co., Inc. investment picks
2014/12/8
WILMINGTON, Del.
Sign-up for CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/12/8
CUC Announces 39.7 MW Generation Expansion Project With BWSC & MAN Diesel & Turbo Canada NewsWire CARIBBEAN UTILITIES COMPANY, LTD.
Sign-up for CUC Announces 39.7 MW Generation Expansion Project With BWSC & MAN Diesel & Turbo investment picks
New Results Presented at the 68th American Epilepsy Society (AES) Annual Meeting HOUSTON , Dec.
Sign-up for Cyberonics Reports Consistently Positive Results From The E-36 And E-37 Studies For VNS Therapy Delivered By AspireSR® Generator investment picks
MCLEAN, Va.
Sign-up for CYREN WebSecurity Wins Biz Award investment picks
The Board of Directors of CYS Investments, Inc. (NYSE: CYS) (the “Company”) today declared a quarterly dividend of $0.30 per share of common stock for the fourth quarter of 2014.
Sign-up for CYS Investments, Inc. Board of Directors Declares Fourth Quarter 2014 Common Stock Dividend of $0.30 Per Share, and Preferred Stock Dividends investment picks
2014/12/8
By Yvonne Lee And Prudence Ho A year-end revival in Hong Kong's IPO market has brought what could be the world's biggest property-stock listing to the city.
Sign-up for Dalian Wanda Is Raising Up To $3.8 Billion at Discount investment picks
WASHINGTON , Dec.
Sign-up for Danaher To Webcast Investor And Analyst Meeting investment picks
Company Names John O.
Sign-up for Darling Ingredients Inc. Announces Appointment Of New Chief Financial Officer investment picks
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
2014/12/8
College Mentors for Kids will honor David Becker, Chairman & CEO, First Internet Bancorp, at the 2015 Inspire Awards with the Lifetime Achievement Award in Mentoring.
Sign-up for David Becker, Chairman & CEO, First Internet Bancorp, to be Honored at the 2015 Inspire Awards investment picks
dELiA*s, Inc. (NASDAQ:DLIA), an omni-channel retail company primarily marketing to teenage girls, announced today that it, along with certain of its subsidiaries (collectively, the “Company”), has filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York in White Plains, NY (the “Bankruptcy Court”) on December 7, 2014.
Sign-up for dELiA*s, Inc. and Certain of Its Affiliates File for Chapter 11 Bankruptcy investment picks
Delta One, First Class and Delta Comfort+ offer premium experiences; Main Cabin and Basic Economy offer options for all customers ATLANTA , Dec.
Sign-up for Delta Redefines Cabin, Upgrades Premium Economy Options investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Correction to Deutsche Bank Story to Delta Redefines Cabin, Upgrades Premium Economy Options
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent